Processa Pharmaceuticals (PCSA)
Market Price (6/15/2026): $2.17 | Market Cap: $5.7 MilSector: Health Care | Industry: Biotechnology
Processa Pharmaceuticals (PCSA)
Market Price (6/15/2026): $2.17Market Cap: $5.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, and Oncology Treatments. | Weak multi-year price returns2Y Excs Rtn is -134%, 3Y Excs Rtn is -173% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -14 Mil Stock price has recently run up significantly6M Rtn6 month market price return is 704% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -252% High stock price volatilityVol 12M is 5461% Key risksPCSA key risks include [1] substantial doubt about its ability to continue as a going concern due to significant financial instability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, and Oncology Treatments. |
| Weak multi-year price returns2Y Excs Rtn is -134%, 3Y Excs Rtn is -173% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -14 Mil |
| Stock price has recently run up significantly6M Rtn6 month market price return is 704% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -252% |
| High stock price volatilityVol 12M is 5461% |
| Key risksPCSA key risks include [1] substantial doubt about its ability to continue as a going concern due to significant financial instability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Processa Pharmaceuticals (PCSA) stock has remained largely at the same level since 2/28/2026 because of the following key factors:
1. Mixed Fiscal Q1 2026 Financial Results. Processa Pharmaceuticals reported an actual loss per share of -$1.29 for fiscal Q1 2026 (ended March 31, 2026), missing analyst expectations of -$1.00 by 29.00%. However, this represented a significant improvement from the basic and diluted loss per share of -$7.58 reported in the same quarter of the prior year, with the net loss at USD 3.38 million compared to USD 2.83 million a year ago. This combination of a short-term earnings miss but a substantial year-over-year improvement in loss per share likely created a balanced investor reaction, contributing to the stock's relatively stable trend.
2. Potential Future Value from Strategic Licensing Deal. The company entered into a binding term sheet with Intact Therapeutics for an exclusive option to license PCS12852, a gastroparesis drug candidate, with potential milestone payments up to $452.5 million. This includes a $2.5 million option exercise fee, up to $20 million in development/regulatory milestones, and $432.5 million in commercial milestones, along with 12% royalties and a 3.5% equity stake. While these payments are largely prospective, the announcement of this high-value potential deal likely provided a long-term positive outlook, mitigating any downward pressure on the stock from immediate operational losses.
Show more
Stock Movement Drivers
Fundamental Drivers
The 0.0% change in PCSA stock from 2/28/2026 to 6/14/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282026 | 6142026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.17 | 2.17 | 0.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 3 | -27.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 6/14/2026| Return | Correlation | |
|---|---|---|
| PCSA | 0.0% | |
| Market (SPY) | 8.4% | 20.0% |
| Sector (XLV) | -3.6% | -1.0% |
Fundamental Drivers
The -66.5% change in PCSA stock from 11/30/2025 to 6/14/2026 was primarily driven by a -27.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 6142026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.47 | 2.17 | -66.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 3 | -27.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 6/14/2026| Return | Correlation | |
|---|---|---|
| PCSA | -66.5% | |
| Market (SPY) | 9.2% | -12.1% |
| Sector (XLV) | -1.6% | -2.0% |
Fundamental Drivers
The -70.3% change in PCSA stock from 5/31/2025 to 6/14/2026 was primarily driven by a -85.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312025 | 6142026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.31 | 2.17 | -70.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 3 | -85.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2025 to 6/14/2026| Return | Correlation | |
|---|---|---|
| PCSA | -70.3% | |
| Market (SPY) | 27.3% | -9.3% |
| Sector (XLV) | 18.0% | -1.9% |
Fundamental Drivers
The -99.3% change in PCSA stock from 5/31/2023 to 6/14/2026 was primarily driven by a -98.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312023 | 6142026 | Change |
|---|---|---|---|
| Stock Price ($) | 310.00 | 2.17 | -99.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 3 | -98.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2023 to 6/14/2026| Return | Correlation | |
|---|---|---|
| PCSA | -99.3% | |
| Market (SPY) | 84.5% | -4.0% |
| Sector (XLV) | 26.5% | -0.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PCSA Return | -26% | -78% | -70% | -87% | -87% | -18% | -100% |
| Peers Return | 43% | -20% | 3% | 78% | -33% | -16% | 17% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| PCSA Win Rate | 33% | 25% | 25% | 25% | 33% | 50% | |
| Peers Win Rate | 46% | 50% | 46% | 58% | 75% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| PCSA Max Drawdown | -69% | -79% | -86% | -88% | -100% | -50% | |
| Peers Max Drawdown | -41% | -46% | -34% | -26% | -59% | -39% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ATYR, AVLN, CNXU, COAG.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/12/2026 (YTD)
How Low Can It Go
| Event | PCSA | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -55.6% | -9.5% |
| % Gain to Breakeven | 125.3% | 10.5% |
| Time to Breakeven | 7 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -48.3% | -6.7% |
| % Gain to Breakeven | 93.6% | 7.1% |
| Time to Breakeven | 266 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -17.9% | -33.7% |
| % Gain to Breakeven | 21.9% | 50.9% |
| Time to Breakeven | 1 days | 140 days |
In The Past
Processa Pharmaceuticals's stock fell -55.6% during the Summer-Fall 2023 Five Percent Yield Shock. Such a loss loss requires a 125.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PCSA | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -55.6% | -9.5% |
| % Gain to Breakeven | 125.3% | 10.5% |
| Time to Breakeven | 7 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -48.3% | -6.7% |
| % Gain to Breakeven | 93.6% | 7.1% |
| Time to Breakeven | 266 days | 31 days |
In The Past
Processa Pharmaceuticals's stock fell -55.6% during the Summer-Fall 2023 Five Percent Yield Shock. Such a loss loss requires a 125.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Processa Pharmaceuticals (PCSA)
AI Analysis | Feedback
An early-stage Moderna, focused on developing a diverse pipeline of experimental drugs for various conditions, all still in clinical trials.
Like an aspiring Gilead Sciences, building a portfolio of potential new medicines across different therapeutic areas, with no approved products yet.
AI Analysis | Feedback
```html- PCS499: An oral tablet in Phase 2B clinical trials for treating ulcerative and non-ulcerative necrobiosis lipoidica.
- PCS12852: A novel selective 5-HT4 receptor agonist in Phase 2A clinical trials for gastroparesis, chronic constipation, constipation-predominant IBS, and functional dyspepsia.
- PCS3117: A cytosine analog in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer.
- PCS6422: An oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase in Phase 1B clinical trials for metastatic colorectal and breast cancer.
- PCS11T: An analog of SN38 and irinotecan drug being developed for the treatment of various cancers.
AI Analysis | Feedback
Processa Pharmaceuticals (PCSA) is a clinical stage biopharmaceutical company focused on the development of drug products that are currently in various phases of clinical trials (Phase 1B, 2A, and 2B). As such, its drug candidates are not yet approved for commercial sale, and the company is not currently selling products to end-users, whether they be other companies or individual patients. Therefore, Processa Pharmaceuticals does not have major customers in the traditional commercial sense.
AI Analysis | Feedback
nullAI Analysis | Feedback
George Ng, Chief Executive Officer
Mr. Ng was appointed CEO in August 2023. He is a seasoned life sciences industry executive and a partner at PENG Life Science Ventures. Mr. Ng co-founded and served as President of Scilex Pharmaceuticals, Inc. (now Scilex Holding Co), guiding it through development, clinical trials, FDA approval, a $140 million financing, commercial launch of its first FDA-approved drug product, and its eventual sale. He has held various senior management and board positions with publicly traded and private biotechnology and pharmaceutical companies, including Sorrento Therapeutics, Inc., BioDelivery Sciences International, Inc., Spectrum Pharmaceuticals, Inc., and Alpharma, Inc. (now part of Pfizer Inc.). His extensive experience spans all stages of drug development, from preclinical to commercial, and he has been involved in taking companies public and selling them.
Russell L. Skibsted, Chief Financial Officer
Mr. Skibsted assumed the role of CFO in late 2025/early 2026, succeeding James Stanker. He brings nearly three decades of experience in the pharmaceutical industry, with expertise in financial management, global business development, capital markets, investor relations, and operations. He has worked with both public and private life sciences companies across various development stages. Most recently, he was Senior Vice President and CFO of Alimera Sciences, a publicly traded ophthalmic pharmaceuticals company that is being acquired by ANI Pharmaceuticals. His previous roles include Executive Vice President, CFO, and Chief Business Officer at Rockwell Medical, and CFO at BioTime (now Lineage Cell Therapeutics). Early in his career, Mr. Skibsted served as Portfolio Management Partner and CFO at Asset Management Company, a Silicon Valley venture capital firm, and as Vice President at GE Capital Services Structured Finance Group.
David Young, Pharm.D., Ph.D., President of Research and Development and Founder
Dr. Young is an initial founder of Processa Pharmaceuticals in 2011 and currently serves as President of Research and Development, having previously held the roles of President and CEO. With over 30 years of pharmaceutical research, drug development, and corporate experience, he was also the Founder and CEO of Promet Therapeutics, LLC. As Chief Scientific Officer of Questcor Pharmaceuticals from 2009 to 2014, Dr. Young was instrumental in modernizing the Acthar Gel label and securing FDA approval in Infantile Spasms. Questcor was subsequently acquired by Mallinckrodt Pharmaceuticals in 2014 for approximately $5.6 billion. He also founded and was CEO of GloboMax LLC, a CRO acquired by ICON plc in 2003.
Patrick Lin, Chief Business & Strategy Officer and Founder
Mr. Lin co-founded Processa Pharmaceuticals in 2011 and has over 20 years of financing and investing experience in the Biopharm Sector. He was a Co-Founder and Chairman of the Board of Promet Therapeutics, LLC, and is the Founder and Managing Partner of Primarius Capital, a family office managing public and private investments. Mr. Lin was also a Co-Founding Partner of E*Offering and held positions at various Wall Street banking and brokerage firms, including Robertson Stephens & Co., E*Offering, and Goldman Sachs & Co.
Sian Bigora, Pharm.D., Chief Development and Regulatory Officer
Dr. Bigora possesses over 20 years of experience in pharmaceutical research, regulatory strategy, and drug development. She was a Co-Founder, Director, and Chief Development Officer at Promet Therapeutics, LLC. Prior to joining Processa, Dr. Bigora served as Vice President of Regulatory Affairs at Questcor Pharmaceuticals from 2009 to 2015, where she led efforts to modernize the Acthar Gel label and obtain FDA approval in Infantile Spasms. Questcor was acquired by Mallinckrodt Pharmaceuticals in 2014.
AI Analysis | Feedback
The key risks for Processa Pharmaceuticals (PCSA) are primarily associated with the inherent challenges of being a clinical-stage biopharmaceutical company, coupled with significant financial hurdles.
- Clinical Trial and Regulatory Approval Risk: As a clinical-stage company, Processa Pharmaceuticals' business success is entirely dependent on the successful development, clinical trial outcomes, and eventual regulatory approval of its drug candidates. The company currently has multiple drug candidates, including PCS499, PCS12852, PCS3117, PCS6422, and PCS11T, in various phases of clinical trials, ranging from Phase 1B to Phase 2B. Clinical trials are notoriously expensive, time-consuming, and carry a high rate of failure, with less than 12% of candidate drugs typically making it to market. Even if trials are successful, there is no guarantee that regulatory bodies, such as the FDA, will grant approval.
- Financial and Funding Risk, including Nasdaq Delisting: Processa Pharmaceuticals operates as a clinical-stage entity without product revenue and is experiencing rapid cash burn, leading to projected net losses for the foreseeable future. This necessitates a heavy reliance on external funding to sustain operations and research and development activities. Furthermore, the company has received a notification from Nasdaq due to its common stock's bid price falling below the minimum requirement, putting it at risk of delisting from The Nasdaq Capital Market. This delisting risk can severely impact its ability to attract investment and raise necessary capital. The need for continuous funding also exposes shareholders to potential dilution as the company may issue more shares to raise capital.
- Commercialization and Market Acceptance Risk: Even if Processa Pharmaceuticals successfully navigates clinical trials and secures regulatory approvals for its drug candidates, it faces the substantial risk of commercialization failure. Factors such as market acceptance, intense competition, pricing pressures, and the imperative to demonstrate sufficient value to justify drug costs can impede commercial success. Without a clear and favorable market position, the company may struggle to generate significant revenue from its approved products.
AI Analysis | Feedback
nullAI Analysis | Feedback
```htmlAddressable Market Sizes for Processa Pharmaceuticals' Main Products
PCS499 (Ulcerative and Non-Ulcerative Necrobiosis Lipoidica)
- The global Necrobiosis Lipoidica Diabeticorum (NLD) market is estimated to be valued at approximately USD 5.1 billion in 2025 and is projected to reach USD 9.1 billion by 2035, growing at a Compound Annual Growth Rate (CAGR) of 6.0%. North America is a key growth region in this market.
PCS12852 (Gastroparesis, Chronic Constipation, Constipation-Predominant Irritable Bowel Syndrome, and Functional Dyspepsia)
- Gastroparesis: The global gastroparesis treatment market was valued at approximately USD 6.63 billion in 2024 and is projected to reach USD 10.45 billion by 2034, expanding at a CAGR of 4.65%. The U.S. gastroparesis treatment market size was approximately USD 1.95 billion in 2024 and is projected to be worth around USD 3.13 billion by 2034.
- Chronic Constipation: The global Chronic Idiopathic Constipation Treatment market size is projected to be approximately USD 11.56 billion in 2025. North America held a significant market share, with the U.S. market for Chronic Idiopathic Constipation Treatment valued at approximately USD 3.37 billion in 2025.
- Constipation-Predominant Irritable Bowel Syndrome (IBS-C): The IBS-C segment of the global Irritable Bowel Syndrome Treatment market was valued at approximately USD 1.11 billion in 2024. The global irritable bowel syndrome treatment market itself is projected to grow from USD 3.84 billion in 2024 to USD 6.75 billion by 2030.
- Functional Dyspepsia: The global functional dyspepsia drug market is projected to achieve a valuation of approximately USD 10.3 billion by 2024 and is expected to increase to USD 16.4 billion by 2034. North America is the largest market for functional dyspepsia drugs, accounting for approximately 45% of the global market share. Based on this, the U.S. market for functional dyspepsia drugs is estimated to be approximately USD 4.63 billion in 2024 (45% of USD 10.3 billion).
PCS3117 (Pancreatic and Non-Small Cell Lung Cancer)
- Pancreatic Cancer: The global pancreatic cancer market size is calculated at approximately USD 3.25 billion in 2025 and is projected to surpass around USD 10.25 billion by 2034. North America is identified as the largest market, with the U.S. being a dominant contributor. The U.S. pancreatic cancer treatment market accounted for approximately USD 1.13 billion in 2025 (estimated based on North America's share of global market).
- Non-Small Cell Lung Cancer (NSCLC): The global non-small cell lung cancer market is estimated to be valued at approximately USD 28.61 billion in 2025 and is expected to reach USD 54.38 billion by 2032. North America is expected to lead the global NSCLC market in 2025 with a 38.7% share, implying a U.S. market size of approximately USD 11.08 billion in 2025 (38.7% of USD 28.61 billion).
PCS6422 (Metastatic Colorectal and Breast Cancer)
- Metastatic Colorectal Cancer: The global Metastatic Colorectal Cancer market is valued at approximately USD 7.68 billion in 2025 and is predicted to reach USD 19.86 billion by 2035. The United States accounted for more than USD 6 billion in 2024 within the 7MM (7 Major Markets).
- Breast Cancer: The global breast cancer drugs market size was estimated at approximately USD 36.62 billion in 2024 and is projected to reach USD 69.72 billion by 2033. The North America breast cancer drugs market held the largest share of 37.28% of the global market in 2024, indicating a U.S. market size of approximately USD 13.65 billion in 2024 (37.28% of USD 36.62 billion).
AI Analysis | Feedback
Processa Pharmaceuticals (PCSA), a clinical-stage biopharmaceutical company, is positioned for potential future revenue growth primarily through the advancement and commercialization of its pipeline assets and strategic partnerships over the next two to three years. The company has explicitly shifted its focus to "next-generation chemotherapy drugs" (NGC) and is strategically managing its non-oncology assets to unlock value.
Here are 3-5 expected drivers of future revenue growth:
- Advancement and potential commercialization or partnership of NGC-Cap (PCS6422 + capecitabine) for metastatic breast cancer: NGC-Cap is Processa's lead oncology asset and a top priority. The company completed enrollment for the formal interim analysis of its Phase 2 study in metastatic breast cancer in January 2026, with full safety and efficacy results from this cohort anticipated in early 2026. Positive clinical trial results and subsequent progression to later-stage trials, regulatory filings, and ultimately market approval or a significant partnership, would be a primary driver of revenue growth.
- Milestone payments and royalties from the PCS12852 licensing agreement with Intact Therapeutics: In June 2025, Processa entered into a binding term sheet with Intact Therapeutics, granting them an exclusive option to license PCS12852 for gastroparesis and other gastrointestinal motility disorders. This agreement makes Processa eligible to receive a $2.5 million option exercise fee, up to $20 million in development and regulatory milestone payments, and over $432.5 million in commercial milestone payments, along with double-digit royalties on worldwide net sales (excluding South Korea). The exercise of the option and the achievement of development and regulatory milestones within the next 2-3 years would generate non-dilutive revenue.
- Advancement of PCS499 in rare kidney disease (FSGS) and securing strategic partnerships: While initially developed for necrobiosis lipoidica, Processa is now designing an adaptive Phase 2/3 study for PCS499 in rare kidney disease (focal segmental glomerulosclerosis or FSGS), with discussions planned with the FDA. The company is also establishing a dedicated subsidiary for PCS499 to enhance strategic flexibility for capital raising and potential partnership discussions. Successful progression of clinical trials and the formation of strategic partnerships to further develop and potentially commercialize PCS499 would represent a significant revenue growth driver.
AI Analysis | Feedback
Share Issuance
- Processa Pharmaceuticals completed several equity offerings, including a $7 million public offering in June 2025, which involved 28,000,000 shares of common stock (or pre-funded warrants) and common warrants.
- In June 2025, the company raised approximately $6.3 million (gross proceeds) through a public offering of 14.3 million shares, pre-funded warrants, and common warrants, with proceeds intended for clinical trials and working capital.
- To provide flexibility for future offerings and maintain Nasdaq compliance, the Board proposed increasing authorized common stock from 100,000,000 to 1,000,000,000 shares in August 2025, following a 1:20 reverse stock split in January 2024 and a 1:25 reverse stock split in December 2025.
Inbound Investments
- Processa Pharmaceuticals secured an undisclosed strategic investment in August 2025, aiming to support operations, enhance financial flexibility, and explore cryptocurrency treasury strategies.
- In October 2025, Chiliz Group Ltd., a blockchain-focused investment firm, acquired a 10.9% stake in Processa Pharmaceuticals for approximately $1.24 million through a Securities Purchase Agreement.
- The company is set to receive payments totaling $2.5 million from Intact Therapeutics as part of a licensing agreement for PCS12852, in addition to an initial $20,000 non-refundable standstill payment.
Outbound Investments
- As part of a licensing agreement for its drug candidate PCS12852 in June 2025, Processa Pharmaceuticals will acquire a 3.5% equity interest in Intact Therapeutics.
Capital Expenditures
- Processa Pharmaceuticals reported $0 in capital expenditures in Q3 2024, indicating minimal investment in long-term assets and infrastructure.
- The primary focus of capital allocation, beyond operating expenses, is directed towards funding clinical development programs, such as the Phase 2 clinical trial for NCG-Cap, as well as for working capital and general corporate purposes.
- Research and Development expenses were $1.7 million in Q3 2025, highlighting the company's investment in its drug pipeline.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 18.13 |
| Mkt Cap | 56.5 |
| Rev LTM | 6,109 |
| Op Inc LTM | 2,324 |
| FCF LTM | 1,849 |
| FCF 3Y Avg | 983 |
| CFO LTM | 2,114 |
| CFO 3Y Avg | 1,195 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.1% |
| Rev Chg 3Y Avg | 9.9% |
| Rev Chg Q | 7.8% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | 597.1% |
| Op Inc Chg 3Y Avg | 184.3% |
| Op Mgn LTM | 38.2% |
| Op Mgn 3Y Avg | 24.1% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 34.7% |
| CFO/Rev 3Y Avg | 21.5% |
| FCF/Rev LTM | 30.4% |
| FCF/Rev 3Y Avg | 17.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 56.5 |
| P/S | 9.3 |
| P/Op Inc | 11.9 |
| P/EBIT | 11.0 |
| P/E | 12.8 |
| P/CFO | 13.1 |
| Total Yield | -122.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -2,037.7% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -11.8% |
| 3M Rtn | -24.0% |
| 6M Rtn | -11.6% |
| 12M Rtn | -24.1% |
| 3Y Rtn | -24.1% |
| 1M Excs Rtn | -7.3% |
| 3M Excs Rtn | -36.1% |
| 6M Excs Rtn | -18.7% |
| 12M Excs Rtn | -47.5% |
| 3Y Excs Rtn | -98.2% |
Price Behavior
| Market Price | $2.17 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/20/2018 | |
| Distance from 52W High | -81.9% | |
| 50 Days | 200 Days | |
| DMA Price | $2.71 | $4.22 |
| DMA Trend | down | up |
| Distance from DMA | -20.1% | -48.5% |
| 3M | 1YR | |
| Volatility | 119.1% | 5,493.5% |
| Downside Capture | 560.09 | -232.65 |
| Upside Capture | 233.41 | -293.76 |
| Correlation (SPY) | 23.1% | -9.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.13 | 3.10 | 0.66 | -82.19 | -46.14 | -8.63 |
| Up Beta | 5.09 | 1.49 | -0.79 | 0.21 | 0.39 | 0.37 |
| Down Beta | -0.36 | -4.16 | -3.41 | -188.88 | -101.11 | -13.55 |
| Up Capture | 143% | 303% | 287% | -179% | -70% | -7% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 6 | 18 | 29 | 56 | 118 | 323 |
| Down Capture | 551% | 866% | 240% | -3235% | -921% | 87% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 13 | 21 | 31 | 64 | 127 | 406 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PCSA | |
|---|---|---|---|---|
| PCSA | -78.4% | 5,461.0% | 0.96 | - |
| Sector ETF (XLV) | 15.4% | 15.0% | 0.74 | -1.9% |
| Equity (SPY) | 24.9% | 12.3% | 1.52 | -9.4% |
| Gold (GLD) | 25.5% | 27.4% | 0.81 | 3.2% |
| Commodities (DBC) | 30.1% | 19.0% | 1.25 | 6.1% |
| Real Estate (VNQ) | 13.5% | 13.5% | 0.69 | 2.3% |
| Bitcoin (BTCUSD) | -41.7% | 42.2% | -1.16 | -3.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PCSA | |
|---|---|---|---|---|
| PCSA | -77.0% | 2,447.0% | 0.41 | - |
| Sector ETF (XLV) | 6.4% | 14.8% | 0.25 | -0.4% |
| Equity (SPY) | 13.5% | 17.1% | 0.61 | -2.4% |
| Gold (GLD) | 16.8% | 18.2% | 0.75 | 2.4% |
| Commodities (DBC) | 8.4% | 19.4% | 0.33 | 3.0% |
| Real Estate (VNQ) | 2.8% | 18.8% | 0.05 | 1.4% |
| Bitcoin (BTCUSD) | 13.6% | 54.4% | 0.44 | -1.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PCSA | |
|---|---|---|---|---|
| PCSA | -44.9% | 2,281.1% | 0.39 | - |
| Sector ETF (XLV) | 9.7% | 16.6% | 0.47 | -0.4% |
| Equity (SPY) | 15.3% | 17.9% | 0.73 | -2.3% |
| Gold (GLD) | 12.5% | 16.1% | 0.64 | 2.3% |
| Commodities (DBC) | 6.7% | 18.0% | 0.29 | 2.8% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 1.3% |
| Bitcoin (BTCUSD) | 60.3% | 66.8% | 1.00 | -0.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/31/2023 | 4.2% | -2.0% | 43.8% |
| 11/8/2022 | -4.7% | -4.2% | -17.5% |
| 8/12/2022 | 2.4% | 3.3% | -13.5% |
| 8/13/2021 | -7.5% | -9.7% | 19.7% |
| 5/13/2021 | 1.5% | 11.4% | 10.7% |
| 3/25/2021 | -0.9% | -7.6% | -26.0% |
| SUMMARY STATS | |||
| # Positive | 3 | 2 | 3 |
| # Negative | 3 | 4 | 3 |
| Median Positive | 2.4% | 7.4% | 19.7% |
| Median Negative | -4.7% | -5.9% | -17.5% |
| Max Positive | 4.2% | 11.4% | 43.8% |
| Max Negative | -7.5% | -9.7% | -26.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/18/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/20/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
Insider Activity
Updated 6/1/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Young, David | Pres. Research & Development | Direct | Buy | 6012026 | 2.57 | 1,786 | 4,590 | 44,027 | Form |
| 2 | Skibsted, Russell | Chief Financial Officer | Direct | Buy | 6012026 | 2.57 | 2,292 | 5,890 | 27,648 | Form |
| 3 | Ng, George K | Chief Executive Officer | Direct | Buy | 6012026 | 2.57 | 2,129 | 5,472 | 25,623 | Form |
| 4 | Lin, Patrick | Chief Business - Strategy Off | Direct | Buy | 6012026 | 2.57 | 1,582 | 4,066 | 23,582 | Form |
| 5 | Guy, Wendy | Chief Administrative Officer | Direct | Buy | 6012026 | 2.57 | 1,829 | 4,701 | 25,289 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.